(TYRA) Tyra Biosciences - Ratings and Ratios
FGFR Inhibitor, Precision Platform, Solid Tumors, Skeletal Dysplasia
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 63.7% |
| Value at Risk 5%th | 97.3% |
| Relative Tail Risk | -7.14% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.12 |
| Alpha | 52.70 |
| CAGR/Max DD | 0.57 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.524 |
| Beta | 1.093 |
| Beta Downside | 0.856 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.32% |
| Mean DD | 28.77% |
| Median DD | 21.18% |
Description: TYRA Tyra Biosciences October 23, 2025
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage biotech focused on precision medicines that target fibroblast growth factor receptor (FGFR) pathways. Its proprietary SNÅP platform iteratively captures molecular “snapshots” to anticipate genetic alterations, accelerating the design of oncology and genetically defined therapies. The lead candidate, TYRA-300, is currently in Phase II trials for metastatic urothelial carcinoma and a broader solid-tumor indication, while parallel programs explore TYRA-300 for FGFR3-driven skeletal dysplasias (e.g., achondroplasia) and TYRA-200 for biliary and solid tumors; TYRA-430 targets hepatocellular carcinoma.
As of the latest 10-Q (Q2 2024), Tyra reported approximately $150 million in cash and marketable securities, giving it an estimated 18-month runway at current burn rates-a critical KPI for a company without product revenue. The global FGFR-targeted drug market is projected to exceed $5 billion by 2028, driven by increasing prevalence of FGFR-altered cancers and the growing pipeline of precision-medicine candidates. Moreover, biotech R&D spending in the U.S. has risen ~10 % year-over-year, supporting a favorable financing environment for companies like Tyra that are advancing multiple IND-enabling programs.
If you’re evaluating high-growth biotech opportunities, a deeper dive into Tyra’s pipeline milestones and cash-flow assumptions on ValueRay could help clarify the risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-111.7m TTM) > 0 and > 6% of Revenue (6% = 29.8k TTM) |
| FCFTA -0.30 (>2.0%) and ΔFCFTA -13.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 53.5k% (prev 70.4k%; Δ -16.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.30 (>3.0%) and CFO -91.1m > Net Income -111.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 17.71 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (59.7m) change vs 12m ago 1.35% (target <= -2.0% for YES) |
| Gross Margin 42.94% (prev 4.98%; Δ 37.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 0.15% (prev 0.13%; Δ 0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.95 (EBITDA TTM -122.4m / Interest Expense TTM -11.2m) >= 6 (WARN >= 3) |
Altman Z'' -16.88
| (A) 0.88 = (Total Current Assets 281.2m - Total Current Liabilities 15.9m) / Total Assets 301.9m |
| (B) -1.12 = Retained Earnings (Balance) -337.4m / Total Assets 301.9m |
| warn (B) unusual magnitude: -1.12 — check mapping/units |
| (C) -0.36 = EBIT TTM -122.9m / Avg Total Assets 341.2m |
| (D) -15.79 = Book Value of Equity -337.0m / Total Liabilities 21.3m |
| Total Rating: -16.88 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.11
| 1. Piotroski 1.0pt |
| 2. FCF Yield -9.62% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 0.46 |
| 6. ROIC - WACC (= -41.24)% |
| 7. RoE -35.76% |
| 8. Rev. Trend 20.41% |
| 9. EPS Trend -69.01% |
What is the price of TYRA shares?
Over the past week, the price has changed by +12.73%, over one month by +53.49%, over three months by +104.08% and over the past year by +75.93%.
Is TYRA a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TYRA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32 | 25.4% |
| Analysts Target Price | 32 | 25.4% |
| ValueRay Target Price | 28.3 | 10.9% |
TYRA Fundamental Data Overview December 13, 2025
P/B = 4.2411
Beta = 1.087
Revenue TTM = 496.0k USD
EBIT TTM = -122.9m USD
EBITDA TTM = -122.4m USD
Long Term Debt = 5.92m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 456.0k USD (from shortTermDebt, last quarter)
Debt = 5.92m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -56.0m USD (from netDebt column, last quarter)
Enterprise Value = 948.4m USD (1.22b + Debt 5.92m - CCE 274.9m)
Interest Coverage Ratio = -10.95 (Ebit TTM -122.9m / Interest Expense TTM -11.2m)
FCF Yield = -9.62% (FCF TTM -91.2m / Enterprise Value 948.4m)
FCF Margin = -18.4k% (FCF TTM -91.2m / Revenue TTM 496.0k)
Net Margin = -22.5k% (Net Income TTM -111.7m / Revenue TTM 496.0k)
Gross Margin = 42.94% ((Revenue TTM 496.0k - Cost of Revenue TTM 283.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.14 (Enterprise Value 948.4m / Total Assets 301.9m)
Interest Expense / Debt = 41.46% (Interest Expense 2.45m / Debt 5.92m)
Taxrate = 21.0% (US default 21%)
NOPAT = -97.1m (EBIT -122.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.71 (Total Current Assets 281.2m / Total Current Liabilities 15.9m)
Debt / Equity = 0.02 (Debt 5.92m / totalStockholderEquity, last quarter 280.5m)
Debt / EBITDA = 0.46 (negative EBITDA) (Net Debt -56.0m / EBITDA -122.4m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -56.0m / FCF TTM -91.2m)
Total Stockholder Equity = 312.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.00% (Net Income -111.7m / Total Assets 301.9m)
RoE = -35.76% (Net Income TTM -111.7m / Total Stockholder Equity 312.3m)
RoCE = -38.62% (EBIT -122.9m / Capital Employed (Equity 312.3m + L.T.Debt 5.92m))
RoIC = -31.09% (negative operating profit) (NOPAT -97.1m / Invested Capital 312.3m)
WACC = 10.15% (E(1.22b)/V(1.22b) * Re(10.04%) + D(5.92m)/V(1.22b) * Rd(41.46%) * (1-Tc(0.21)))
Discount Rate = 10.04% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.85%
Fair Price DCF = unknown (Cash Flow -91.2m)
EPS Correlation: -69.01 | EPS CAGR: -34.68% | SUE: 0.02 | # QB: 0
Revenue Correlation: 20.41 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.57 | Chg30d=-0.003 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=-2.27 | Chg30d=-0.105 | Revisions Net=-1 | Growth EPS=-14.1% | Growth Revenue=+0.0%
Additional Sources for TYRA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle